Key result
Coronary microvascular dysfunction in hypertension marks subclinical end-organ damage and HFpEF.
Why the study?
Hypertension causes functional and structural microvasculature alterations promoting coronary microvascular dysfunction, making it important to identify microvascular angina and understand its pathophysiological mechanisms, diagnostic approaches, and therapeutic modalities.
CMD is a crucial subclinical marker of end-organ damage in hypertension, highlighting the importance of targeted non-invasive and invasive diagnostic evaluation in hypertensive patients with non-obstructive chest pain.
May support CMD evaluation in select hypertensive patients; leaves open prospective validation for HFpEF risk stratification.
Coronary microvascular dysfunction (CMD) is a clinical entity linked with various risk factors that significantly affect cardiac morbidity and mortality. Hypertension, one of the most important, causes both functional and structural alterations in the microvasculature, promoting the occurrence and progression of microvascular angina. Endothelial dysfunction and capillary rarefaction play the most significant role in the development of CMD among patients with hypertension. CMD is also related to several hypertension-induced morphological and functional changes in the myocardium in the subclinical and early clinical stages, including left ventricular hypertrophy, interstitial myocardial fibrosis, and diastolic dysfunction. This indicates the fact that CMD, especially if associated with hypertension, is a subclinical marker of end-organ damage and heart failure, particularly that with preserved ejection fraction. This is why it is important to search for microvascular angina in every patient with hypertension and chest pain not associated with obstructive coronary artery disease. Several highly sensitive and specific non-invasive and invasive diagnostic modalities have been developed to evaluate the presence and severity of CMD and also to investigate and guide the treatment of additional complications that can affect further prognosis. This comprehensive review provides insight into the main pathophysiological mechanisms of CMD in hypertensive patients, offering an integrated diagnostic approach as well as an overview of currently available therapeutical modalities.
No takes yet. Share an insight, caveat, or question.
Zdravković et al. (2023) conducted a review in Coronary microvascular dysfunction and hypertension. Hypertension was evaluated. Coronary microvascular dysfunction, especially when associated with hypertension, is a subclinical marker of end-organ damage and heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: